A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : delta9-THC / delta9-tetrahydrocannabinol

[Related PubMed/MEDLINE]
Total Number of Papers: 140
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   delta9-THC  (>> Co-occurring Abbreviation)
Long Form:   delta9-tetrahydrocannabinol
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2014 Determination of main tetrahydrocannabinoids by GC-MS: impact of protein precipitation by acetonitrile on solid phase extraction of cannabinoids from human serum. ---
2013 [Usefulness of the initial medical examination on matters relating to persons suspected of driving under the influence of amphetamine and its analogs or delta9-tetrahydrocannabinol based on the materials the Department of Forensic Medicine, Pomeranian Medical University in Szczecin]. ---
2010 Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption. CBG, MSTFA
2008 Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. MS
2007 Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. CNS, CSF, LC/MS
2007 Determination of delta9-tetrahydrocannabinol in indoor air as an indicator of marijuana cigarette smoking using adsorbent sampling and in-injector thermal desorption gas chromatography-mass spectrometry. ---
2007 The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. CBD, delta9-THCV
2007 Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. 2-AG, AEA, eCB, FAAH, MGL
2006 Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. 2-AG, GIT
10  2006 Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol. ---
11  2005 (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. WT
12  2005 Cannabinoids and cancer. ---
13  2005 Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. CBD, PD
14  2005 Cannabis and driving: the use of LC-MS to detect delta9-tetrahydrocannabinol (delta9-THC) in oral fluid samples. LOD
15  2005 CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. ---
16  2005 Delta9-tetrahydrocannabinol immunochemical studies: haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled delta9-tetrahydrocannabinol. ---
17  2005 Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. ---
18  2005 Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. ---
19  2005 Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. 2-AG, AEA, eCB
20  2005 Differential effects of two cannabinoid receptor agonists on progressive ratio responding for food and free-feeding in rats. PR
21  2005 Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. pCREB
22  2005 Simultaneous determination of cannabidiol, cannabinol, and delta9-tetrahydrocannabinol in human hair by gas chromatography-mass spectrometry. CBD, CBN, GC-MS, LOD
23  2005 SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. ---
24  2004 A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). CBD, OND
25  2004 Anandamide transport. ---
26  2004 Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. CBD
27  2004 Medicinal cannabis extracts for the treatment of multiple sclerosis. ---
28  2004 Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain. ---
29  2003 Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. DMN, LOS, NTS
30  2002 Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. MS
31  2002 Estrogen improves response accuracy and attenuates the disruptive effects of delta9-THC in ovariectomized rats responding under a multiple schedule of repeated acquisition and performance. ---
32  2002 Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat. DHT, PENK, PVN, VMN
33  2002 Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction. ---
34  2002 SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. ---
35  2002 The cannabinoid receptors. ---
36  2001 Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. MLD-STZ
37  2001 Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. OCB, SCL-90-R, TS
38  2000 Behavioral effects of cannabinoid agents in animals. ---
39  2000 Bidirectional control of airway responsiveness by endogenous cannabinoids. ---
40  2000 Delat9-tetrahydrocannabinol content in cannabis plants of greek origin. ---
41  2000 Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. ---
42  2000 Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. ---
43  2000 Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. SNpc, VTA
44  2000 Effects of lithium dose (UCS) on the acquisition and extinction of a discriminated morphine aversion: tests with morphine and delta9-THC. DTA, UCS
45  2000 Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. ---
46  2000 Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. 2-AG, NArPE
47  2000 Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects. FAAH, PMSF
48  2000 Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. CBC, CBD, CBN
49  2000 Simultaneous analysis of delta9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. 8beta,11-diOH-delta9-THC
50  2000 The effects of acute treatment with delta9-THC on exploratory behaviour and memory in the rat. DA, NA
51  2000 Two distinctive antinociceptive systems in rats with pathological pain. ---
52  1999 Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. ---
53  1999 Cannabis: discrimination of "internal bliss"? ---
54  1999 Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. ---
55  1999 Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. ---
56  1999 Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. ---
57  1999 Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. DA
58  1999 Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. i.c.v
59  1999 Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. ---
60  1999 Inhibition of sea urchin fertilization by fatty acid ethanolamides and cannabinoids. ---
61  1999 Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. NO
62  1999 Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. ---
63  1999 Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats. GABA, GAD
64  1999 The effects of cannabinoids on the brain. ---
65  1999 The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. HGF, MuLV, VIS
66  1998 Cannabinoid/anandamide system and schizophrenia: is there evidence for association? ---
67  1998 Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. ---
68  1998 Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. AP-1, Sp1
69  1998 Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. BALF, LPS
70  1998 Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. DA, FSH, GABA, LH, PRL
71  1998 Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. ARCI
72  1998 Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. ---
73  1998 Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. ---
74  1998 Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. ---
75  1998 Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. 5-HT
76  1998 Perinatal delta9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats. DAT, DOPAC, TH
77  1998 Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. ---
78  1998 Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. PTX
79  1998 The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. CNRs, GABA, GAD
80  1998 Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. ---
81  1997 Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. ---
82  1997 Inhibition of protein kinase A and cyclic AMP response element (CRE)-specific transcription factor binding by delta9-tetrahydrocannabinol (delta9-THC): a putative mechanism of cannabinoid-induced immune modulation. cAMP, CRE, PKA
83  1997 Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. FSH, LH, PRL
84  1996 Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. ---
85  1996 Expression of functional glucagon receptors on lymphoid cells. AFC
86  1979 Effects of cannabinoids on L1210 murine leukemia. III. Inhibition of respiration. delta8-THC
87  1979 Effects of cannabinoids on sperm morphology. CBD, CBN
88  1979 Precoital single doses of delta9-tetrahydrocannabinol block ovulation in the rabbit. hCG, LH, LH-RF, rLH
89  1978 Antagonism of the effects on thermoregulation of delta9-tetrahydrocannabinol by clomipramine in the rat. 5-HIAA
90  1978 Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats. ---
91  1978 Cytogenetic effects of delta-9-tetrahydrocannabinol (delta9-THC) on hamster bone marrow. ---
92  1978 delta9-Tetrahydrocannabinol and 17beta-estradiol bind to different macromolecules in estrogen target tissues. ---
93  1978 Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues. DMHP
94  1978 Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex. ACh, CBD, TRACh
95  1978 Effect of delta9-tetrahydrocannabinol on in vitro sensitization of mouse splenic lymphocytes. PFC
96  1978 Effects of delta9-THC on the synaptosomal uptake of 3H-tryptophan and 3H-choline. ---
97  1978 Relationship between body temperature and brain monoamines during the development of tolerance to delat9-tetrahydrocannabinol in the rat. 5-HIAA, 5-HT, DA, NA
98  1978 Tetrahydrocannabinol and acetylcholinesterase. AChE
99  1978 The effect of delta9-tetrahydrocannabinol on the conversion of [3H]trypotphan to 5-[3H] hydroxytryptamine in the mouse brain. ---
100  1977 Autonomic and cardiovascular effects of chronic delta9-tetrahydrocannabinol administration in mongrel dogs. ---